{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:16:35Z","timestamp":1788336995853,"version":"build-2803163510"},"reference-count":199,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"DOI":"10.3389\/fped.2019.00382","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T04:37:01Z","timestamp":1568954221000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis"],"prefix":"10.3389","volume":"7","author":[{"given":"Marco","family":"Sciveres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nastasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Maggiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4254\/wjh.v6.i7.464","article-title":"Juvenile autoimmune hepatitis: spectrum of the disease","volume":"6","author":"Maggiore","year":"2014","journal-title":"World J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/hep.510250308","article-title":"Autoimmune hepatitis in childhood: a 20-year experience","volume":"25","author":"Gregorio","year":"1997","journal-title":"Hepatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/hep.26454","article-title":"Primary sclerosing cholangitis, autoimmune hepatitis and overlap in Utah children: epidemiology and natural history","volume":"58","author":"Deneau","year":"2013","journal-title":"Hepatology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/S0022-3476(86)80880-0","article-title":"Liver disease associated with anti-liver-kidney microsome antibody in children","volume":"108","author":"Maggiore","year":"1986","journal-title":"J Pediatr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/00005176-199311000-00007","article-title":"Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents","volume":"17","author":"Maggiore","year":"1993","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S0022-3476(05)82892-6","article-title":"Autoimmune hepatitis with initial presentation as acute hepatic failure in young children","volume":"116","author":"Maggiore","year":"1990","journal-title":"J Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.cgh.2007.12.002","article-title":"Autoimmune liver disease associated with celiac disease in childhood: a multicenter study","volume":"6","author":"Caprai","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pcl.2016.08.007","article-title":"Immunodeficiency presenting as an undiagnosed disease","volume":"64","author":"Routes","year":"2017","journal-title":"Pediatr Clin North Am"},{"key":"B9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","article-title":"Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group","volume":"41","author":"Vergani","year":"2004","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1542-3565(04)00354-4","article-title":"Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody","volume":"2","author":"Bridoux-Henno","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1084\/jem.168.2.801","article-title":"Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily","volume":"168","author":"Gueguen","year":"1988","journal-title":"J Exp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0016-5085(99)70186-1","article-title":"Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis","volume":"116","author":"Lapierre","year":"1999","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1136\/gut.46.4.553","article-title":"Liver\/kidney microsomial antibody type 1 targets CYP2D6 on hepatocyte plasma membrane","volume":"46","author":"Muratori","year":"2000","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/hep.20109","article-title":"A murine model of type 2 autoimmune hepatitis: xenoimmunization with human antigens","volume":"39","author":"Lapierre","year":"2004","journal-title":"Hepatology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.dld.2016.03.015","article-title":"Seronegative autoimmune hepatitis in children: spectrum of disorders","volume":"48","author":"Maggiore","year":"2016","journal-title":"Dig Liver Dis"},{"key":"B17","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"131","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1542-3565(04)00396-9","article-title":"Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful?","volume":"2","author":"Ebbeson","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/MPG.0b013e3181fc1e0b","article-title":"Utility of simplified criteria for the diagnosis of autoimmune hepatitis in children","volume":"52","author":"Hiejima","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s12016-014-8432-0","article-title":"Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis","volume":"48","author":"Miao","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0022-3476(84)80477-1","article-title":"Treatment of autoimmune chronic active hepatitis in childhood","volume":"104","author":"Maggiore","year":"1984","journal-title":"J Pediatr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/adc.59.4.330","article-title":"Duration of chronic active hepatitis and the development of cirrhosis","volume":"59","author":"Vegnente","year":"1984","journal-title":"Arch Dis Child"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.3748\/wjg.14.3360","article-title":"Autoimmune paediatric liver disease","volume":"14","author":"Mieli-Vergani","year":"2008","journal-title":"World J Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/MPG.0b013e3182602b20","article-title":"Autoimmune hepatitis in children in Eastern Denmark","volume":"55","author":"Vitfell-Pedersen","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cgh.2010.10.013","article-title":"Immunosuppressive therapy allows recovery from liver failure in children with autoimmune hepatitis","volume":"9","author":"Cuarterolo","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/01.mpg.0000239735.87111.ba","article-title":"Prospective analysis of nonadherence in autoimmune hepatitis: a common problem","volume":"43","author":"Kerkar","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0168-8278(99)80065-8","article-title":"Short-term cyclosporine induces a remission of autoimmune hepatitis in children","volume":"30","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0022-3476(99)70339-2","article-title":"Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis","volume":"135","author":"Debray","year":"1999","journal-title":"J Pediatr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/0016-5085(87)90454-9","article-title":"Cyclosporine treatment of autoimmune chronic active hepatitis","volume":"93","author":"Hyams","year":"1987","journal-title":"Gastroenterology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5009\/gnl15352","article-title":"Diagnosis and management of autoimmune hepatitis: current status and future directions","volume":"10","author":"Czaja","year":"2016","journal-title":"Gut Liver"},{"key":"B33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/01.mpg.0000235975.75120.38","article-title":"Follow-up of children with autoimmune hepatitis treated with cyclosporine","volume":"43","author":"Cuarterolo","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1365-2036.2003.01754.x","article-title":"Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents","volume":"19","author":"Sciveres","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.dld.2018.10.018","article-title":"Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine","volume":"51","author":"Nastasio","year":"2018","journal-title":"Dig Liver Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/MPG.0000000000001530","article-title":"Second-line agents in pediatric patients with autoimmune hepatitis: a systematic review and meta-analysis","volume":"65","author":"Zizzo","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/1573396314666180516130314","article-title":"Old and new treatments for pediatric autoimmune hepatitis","volume":"14","author":"Nastasio","year":"2018","journal-title":"Curr Pediatr Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jpeds.2013.05.042","article-title":"Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","volume":"163","author":"Woynarowski","year":"2013","journal-title":"J Pediatr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jpeds.2013.06.064","article-title":"Budesonide for juvenile autoimmune hepatitis?","volume":"163","author":"Mieli-Vergani","year":"2015","journal-title":"Not yet J Pediatr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3109\/00365521.2014.998271","article-title":"Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use, Scand","volume":"50","author":"Ytting","year":"2015","journal-title":"J. Gastroenterol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.amjmed.2014.06.016","article-title":"Boyer Use of sirolimus in the treatment of refractory autoimmune hepatitis","volume":"127","author":"Chatrath","year":"2014","journal-title":"Am J Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MEG.0b013e32835a68a1","article-title":"Significance of histopathological features in differentiating autoimmune liver disease from non-autoimmune chronic liver disease in children","volume":"25","author":"Kumari","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jhep.2009.02.026","article-title":"Rapidity of treatment response and outcome in type 1 autoimmune hepatitis","volume":"51","author":"Czaja","year":"2009","journal-title":"J Hepatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1053\/jhep.2002.32485","article-title":"Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis","volume":"35","author":"Czaja","year":"2002","journal-title":"Hepatology."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1111\/j.1572-0241.2008.01922.x","article-title":"Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis","volume":"103","author":"Montano-Loza","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/17474124.2018.1453356","article-title":"Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management","volume":"12","author":"Czaja","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.clinbiochem.2017.08.010","article-title":"Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury","volume":"50","author":"Yamaura","year":"2017","journal-title":"Clin Biochem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e0136908","DOI":"10.1371\/journal.pone.0136908","article-title":"Circulating microRNA profiles in patients with type-1 autoimmune hepatitis","volume":"10","author":"Migita","year":"2015","journal-title":"PLoS ONE"},{"key":"B50","doi-asserted-by":"publisher","first-page":"7814","DOI":"10.3748\/wjg.v21.i25.7814","article-title":"miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan","volume":"21","author":"Halasz","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1572-0241.2006.00948.x","article-title":"Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases","volume":"102","author":"Mataki","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/jgh.12340","article-title":"Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis","volume":"29","author":"Matsumoto","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/hepr.12305","article-title":"Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis","volume":"44","author":"Miyake","year":"2014","journal-title":"Hepatol Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/00365521.2016.1233576","article-title":"Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis","volume":"52","author":"Aarslev","year":"2017","journal-title":"Scand J Gastroenterol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/377068a0","article-title":"MIF as a glucocorticoid-induced modulator of cytokine production","volume":"377","author":"Calandra","year":"1995","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/hep.26664","article-title":"The role of macrophage migration inhibitory factor in autoimmune liver disease","volume":"59","author":"Assis","year":"2014","journal-title":"Hepatology."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1007\/s10620-016-4322-z","article-title":"A macrophage migration inhibitory factor polymorphism is associated with autoimmune hepatitis severity in US and Japanese patients","volume":"61","author":"Assis","year":"2016","journal-title":"Dig Dis Sci"},{"key":"B59","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/35051594","article-title":"Identification of the haemoglobin scavenger receptor","volume":"409","author":"Kristiansen","year":"2001","journal-title":"Nature."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/apt.13801","article-title":"Single-centre experience of the macrophage activation marker soluble (s)CD163 -associations with disease activity and treatment response in patients with autoimmune hepatitis","volume":"44","author":"Gronbaek","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/hep.27129","article-title":"Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C","volume":"60","author":"Kazankov","year":"2014","journal-title":"Hepatology."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.humimm.2007.03.010","article-title":"Elevated serum BAFF levels in patients with autoimmune hepatitis","volume":"68","author":"Migita","year":"2007","journal-title":"Hum Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/hep.510300412","article-title":"Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis","volume":"30","author":"Cookson","year":"1999","journal-title":"Hepatology."},{"key":"B65","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0016-5085(99)70458-0","article-title":"Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis","volume":"117","author":"Czaja","year":"1999","journal-title":"Gastroenterology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"9829436","DOI":"10.1155\/2017\/9829436","article-title":"Serum cytokine levels and their relation to clinical features in patients with autoimmune liver diseases","volume":"2017","author":"Akberova","year":"2017","journal-title":"J Immunol Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.dld.2014.02.003","article-title":"The association between Cytotoxic T lymphocyte associated antigen-4, Fas, tumor necrosis factor-\u03b1 gene polymorphisms and autoimmune hepatitis: a meta-analysis","volume":"46","author":"Qin","year":"2014","journal-title":"Dig Liver Dis Jun"},{"key":"B68","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2012.11.010","article-title":"Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis","volume":"58","author":"Weiler-Normann","year":"2013","journal-title":"J Hepatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2169\/internalmedicine.51.6824","article-title":"Adult-onset Still's disease complicated by autoimmune hepatitis: successful treatment with infliximab","volume":"51","author":"Fujii","year":"2012","journal-title":"Intern Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2013.05.046","article-title":"Infliximab as rescue therapy in paediatric autoimmune hepatitis","volume":"59","author":"Rajanayagam","year":"2013","journal-title":"J Hepatol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/MPG.0000000000001759","article-title":"Anti-TNF\u03b1 treatment in children and adolescents with combined inflammatory bowel disease and autoimmune liver disease","volume":"66","author":"Nedelkopoulou","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B72","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","article-title":"Immunogenicity and autoimmunity during anti-TNF-therapy","volume":"13","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B73","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1016\/j.febslet.2011.04.025","article-title":"Contrasting effects of TNF and anti-TNF on activation of effector T cells and regulatory T cells in autoimmunity","volume":"585","author":"Chen","year":"2011","journal-title":"FEBS Lett."},{"key":"B74","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/377348a0","article-title":"Induction of apoptosis in mature T cells by tumour necrosis factor","volume":"377","author":"Zheng","year":"1995","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"E2199","DOI":"10.3390\/ijms19082199","article-title":"Harmful effects and potential benefits of Anti-Tumor Necrosis Factor (TNF)-\u03b1 on the liver","volume":"19","author":"Lopetuso","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpeds.2017.10.071","article-title":"New onset autoimmune hepatitis during anti-tumor necrosis factor-alpha treatment in children","volume":"194","author":"Ricciuto","year":"2018","journal-title":"J Pediatr."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2941","article-title":"TNF, TNF inducers, and TNFR2 agonists: a new path to type 1 diabetes treatment","author":"Faustman","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"B78","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev-pathol-020117-043534","article-title":"Cellular and molecular mechanisms of autoimmune hepatitis, Annu","volume":"13","author":"Webb","year":"2018","journal-title":"Rev. Pathol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/jcp.2005.028613","article-title":"Liver infiltrating mononuclear cells in children with type 1 autoimmune hepatitis","volume":"59","author":"De Biasio","year":"2006","journal-title":"J Clin Pathol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/0140-6736(90)93306-A","article-title":"T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis","volume":"336","author":"Wen","year":"1990","journal-title":"Lancet"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1053\/gast.2002.36058","article-title":"Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8 T-cell activation by bone marrow-derived cells","volume":"123","author":"Bowen","year":"2002","journal-title":"Gastroenterology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1600-0676.1987.tb00361.x","article-title":"Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage","volume":"7","author":"Vergani","year":"1987","journal-title":"Liver"},{"key":"B83","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/hep.26380","article-title":"Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells","volume":"58","author":"Hardtke-Wolenski","year":"2013","journal-title":"Hepatology."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1053\/jhep.1996.v24.pm0008938173","article-title":"Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis","volume":"24","author":"Lohr","year":"1996","journal-title":"Hepatology."},{"key":"B85","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1053\/j.gastro.2005.12.020","article-title":"Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2","volume":"130","author":"Ma","year":"2006","journal-title":"Gastroenterology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/hep.27991","article-title":"Depletion of B cells induces remission of autoimmune hepatitis in mice through reduced antigen presentation and help to T cells","volume":"62","author":"Beland","year":"2015","journal-title":"Hepatology."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/hep.28001","article-title":"B cells expressing CD11b effectively inhibit CD4+ T-cell responses and ameliorate experimental autoimmune hepatitis in mice","volume":"62","author":"Liu","year":"2015","journal-title":"Hepatology."},{"key":"B88","first-page":"676","article-title":"Mechanisms of action of CD20 antibodies","volume":"2","author":"Boross","year":"2012","journal-title":"Am J Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ajg.2013.08.009","article-title":"Rituximab for refractory autoimmune hepatitis: a case report","volume":"14","author":"Al-Busafi","year":"2013","journal-title":"Arab J Gastroenterol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s10620-015-4022-0","article-title":"Refractory autoimmune hepatitis: beyond standard therapy","volume":"61","author":"Rubin","year":"2016","journal-title":"Dig Dis Sci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1097\/MCG.0b013e3180f60b7a","article-title":"Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis","volume":"42","author":"Evans","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1159\/000322693","article-title":"A case of autoimmune hepatitis treated with rituximab","volume":"4","author":"Barth","year":"2010","journal-title":"Case Rep Gastroenterol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1478-3231.2006.01262.x","article-title":"Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature","volume":"26","author":"Santos","year":"2006","journal-title":"Liver Int"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1542\/peds.2011-1900","article-title":"Successful treatment of refractory autoimmune hepatitis with rituximab","volume":"132","author":"D'Agostino","year":"2013","journal-title":"Pediatrics."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.4067\/S0034-98872011001100015","article-title":"Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome","volume":"139","author":"Carey","year":"2011","journal-title":"Rev Med Chil"},{"key":"B97","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/apt.13907","article-title":"International Autoimmune Hepatitis Group (IAIHG)","volume":"45","author":"Liberal","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B98","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1016\/S0168-8278(18)30652-4","article-title":"Rituximab treatment experience in patients with complicated type 1 autoimmune hepatitis in Europe and North America","volume":"68","author":"Than","year":"2018","journal-title":"J Hepatol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR)","volume":"10","author":"Carson","year":"2009","journal-title":"Project Lancet Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/cei.13039","article-title":"B cell activating factor (BAFF) and BAFF receptors: fakes and facts","volume":"190","author":"Ferraccioli","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4 effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 Cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"B104","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00281-009-0188-x","article-title":"Biology of interleukin-22","volume":"32","author":"Wolk","year":"2010","journal-title":"Semin Immunopathol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jaut.2008.04.017","article-title":"Role of Th1 and Th17 cells in organ-specific autoimmunity","volume":"31","author":"Dardalhon","year":"2008","journal-title":"J Autoimmun"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e18909","DOI":"10.1371\/journal.pone.0018909","article-title":"Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression","volume":"6","author":"Zhao","year":"2011","journal-title":"PLoS ONE"},{"key":"B107","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/hep.1840120208","article-title":"Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease","volume":"12","author":"Lobo-Yeo","year":"1990","journal-title":"Hepatology."},{"key":"B108","doi-asserted-by":"publisher","first-page":"436450","DOI":"10.1155\/2015\/436450","article-title":"Therapeutic potential of IL-17-mediated signaling pathway in autoimmune liver diseases","volume":"2015","author":"Zhang","year":"2015","journal-title":"Mediat Inflamm"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1053\/j.gastro.2012.02.041","article-title":"Inhibition of interleukin-17 promotes differentiation of CD25(-) cells into stable T regulatory cells in patients with autoimmune hepatitis","volume":"142","author":"Longhi","year":"2012","journal-title":"Gastroenterology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1093\/rheumatology\/kex301","article-title":"Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study","volume":"56","author":"McInnes","year":"2017","journal-title":"Rheumatology"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2019.1603361","article-title":"US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry","volume":"29","author":"Strober","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"B112","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Baeten","year":"2013","journal-title":"Lancet"},{"key":"B114","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"B116","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"CERTIFI Study Group. Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/bjd.15023","article-title":"Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry","volume":"176","author":"Zweegers","year":"2017","journal-title":"Br J Dermatol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/art.40912","article-title":"Long term outcome of ustekinumab therapy for Beh\u00e7et's disease","author":"Mirouse","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study, Hepatology","volume":"64","author":"Hirschfield","year":"2016"},{"key":"B122","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14712598.2018.1398729","article-title":"A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents","volume":"18","author":"Tonini","year":"2018","journal-title":"Expert Opin Biol Ther."},{"key":"B123","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/DDDT.S41437","article-title":"Tocilizumab in the treatment of rheumatoid arthritis and beyond","volume":"8","author":"Shetty","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"B124","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40272-013-0053-1","article-title":"Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis","volume":"15","author":"Frampton","year":"2013","journal-title":"Pediatric Drugs."},{"key":"B125","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bcp.2019.04.027","article-title":"Treatment of giant cell arteritis","volume":"165","author":"Gonz\u00e1lez-Gay","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B127","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.immuni.2007.11.016","article-title":"T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma","volume":"28","author":"Yang","year":"2008","journal-title":"Immunity"},{"key":"B128","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.bmcl.2012.11.025","article-title":"Small molecule amides as potent ROR-\u03b3 selective modulators Bioorg","volume":"23","author":"Khan","year":"2013","journal-title":"Med Chem Lett."},{"key":"B129","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1572","article-title":"The Foxp3+ regulatory T cell: a jack of all trades, master of regulation","volume":"9","author":"Tang","year":"2008","journal-title":"Nat Immunol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: mechanisms of differentiation and function","volume":"30","author":"Josefowicz","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"B132","doi-asserted-by":"publisher","first-page":"923","DOI":"10.4049\/jimmunol.172.2.923","article-title":"Alloantigen-induced CD25+ CD4+ regulatory T cells can develop in vivo from CD25-CD4?","volume":"172","author":"Karim","year":"2004","journal-title":"J Immunol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"7602","DOI":"10.4049\/jimmunol.0901881","article-title":"CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis","volume":"183","author":"Fletcher","year":"2009","journal-title":"J Immunol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1172\/JCI200423215","article-title":"IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage","volume":"114","author":"O'Garra","year":"2004","journal-title":"J Clin Invest"},{"key":"B135","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.4049\/jimmunol.177.10.6780","article-title":"T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine","volume":"177","author":"Kobie","year":"2006","journal-title":"J Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/hep.25682","article-title":"The impaired immune regulation of autoimmune hepatitis is linked to a defective galectin-9\/tim-3 pathway","volume":"56","author":"Liberal","year":"2012","journal-title":"Hepatology."},{"key":"B137","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3389\/fimmu.2019.00680","article-title":"The pivotal role of regulatory T cells in the regulation of innate immune cells","volume":"10","author":"Okeke","year":"2019","journal-title":"Front Immunol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"3930750","DOI":"10.1155\/2018\/3930750","article-title":"The Role of Autoimmune Regulator (AIRE) in Peripheral Tolerance","volume":"2018","author":"Zhao","year":"2018","journal-title":"J Immunol Res"},{"key":"B139","doi-asserted-by":"publisher","first-page":"89017","DOI":"10.1155\/2007\/89017","article-title":"IPEX as a result of mutations in FOXP3","volume":"2007","author":"Van","year":"2007","journal-title":"Clin Dev Immunol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/nature05479","article-title":"Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression","volume":"445","author":"Wan","year":"2007","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12890-017-0446-y","article-title":"Analysis of long term CD4+CD25highCD127- T-reg cells kinetics in peripheral blood of lung transplant recipients","volume":"17","author":"Piloni","year":"2017","journal-title":"BMC Pulm Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2004.03.008","article-title":"Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease","volume":"41","author":"Longhi","year":"2004","journal-title":"J Hepatol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.4049\/jimmunol.176.7.4484","article-title":"Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis","volume":"176","author":"Longhi","year":"2006","journal-title":"J Immunol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/hep.23792","article-title":"A multifaceted imbalance of T cells with regulatory function characterizes type 1 autoimmune hepatitis","volume":"52","author":"Ferri","year":"2010","journal-title":"Hepatology."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/hep.26583","article-title":"Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis","volume":"59","author":"Grant","year":"2014","journal-title":"Hepatology."},{"key":"B146","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/hep.27884","article-title":"In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression","volume":"62","author":"Liberal","year":"2015","journal-title":"Hepatology."},{"key":"B147","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jhep.2012.02.029","article-title":"FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency","volume":"57","author":"Peiseler","year":"2012","journal-title":"J Hepatol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"e0181107","DOI":"10.1371\/journal.pone.0181107","article-title":"Pediatric autoimmune hepatitis shows a disproportionate decline of regulatory T cells in the liver and of IL-2 in the blood of patients undergoing therapy","volume":"12","author":"Diestelhorst","year":"2017","journal-title":"PLoS ONE"},{"key":"B149","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fimmu.2016.00334","article-title":"Clinical potential of regulatory T cell therapy in liver diseases: an overview and current perspectives","volume":"7","author":"Jeffery","year":"2016","journal-title":"Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hep.26023","article-title":"Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance","volume":"57","author":"Lapierre","year":"2013","journal-title":"Hepatology."},{"key":"B151","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.4049\/jimmunol.0901216","article-title":"Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver","volume":"184","author":"Oo","year":"2010","journal-title":"J Immunol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/hep.28459","article-title":"A pilot study of operational tolerance with a regulatory T cell-based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology."},{"key":"B153","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127 \u2013 T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+CD25highCD127 \u2013 regulatory T cells preserves beta-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes Care"},{"key":"B157","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J Exp Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1084\/jem.20040180","article-title":"CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes","volume":"199","author":"Tarbell","year":"2004","journal-title":"J Exp Med."},{"key":"B160","doi-asserted-by":"publisher","first-page":"e11726","DOI":"10.1371\/journal.pone.0011726","article-title":"Human antigen-specific regulatory T cells generated by T cell receptor gene transfer","volume":"5","author":"Brusko","year":"2010","journal-title":"PLoS ONE"},{"key":"B161","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1002\/eji.201344381","article-title":"Isolation of human antigen-specific regulatory T cells with high suppressive function","volume":"44","author":"Noyan","year":"2014","journal-title":"Eur J Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/j.transproceed.2013.01.073","article-title":"Donor-specific regulatory T cells generated on donor B cells are superior to CD4+CD25high cells in controlling alloimmune responses in human-ized mice","volume":"45","author":"Noyan","year":"2013","journal-title":"Transplant Proc"},{"key":"B163","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.3727\/096368914X683566","article-title":"Generation of human alloantigen-specific regulatory T cells under good manufacturing practice-compliant conditions for cell therapy","volume":"24","author":"Chera\u00ef","year":"2015","journal-title":"Cell Transplant"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"B166","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant"},{"key":"B167","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/hep.24039","article-title":"Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis","volume":"53","author":"Longhi","year":"2011","journal-title":"Hepatology."},{"key":"B168","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1240e","DOI":"10.1002\/hep.21385","article-title":"IL-2 receptor alpha(-\/-) mice and the development of primary biliary cirrhosis","volume":"44","author":"Wakabayashi","year":"2006","journal-title":"Hepatology"},{"key":"B170","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaut.2015.08.016","article-title":"Using GWAS to identify genetic predisposition in hepatic autoimmunity","volume":"66","author":"Webb","year":"2016","journal-title":"J Autoimmun."},{"key":"B171","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/gut.49.1.131","article-title":"Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis","volume":"49","author":"Bo","year":"2001","journal-title":"Gut."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1023\/A:1005506031717","article-title":"Nature and behavior of serum cytokines in type 1 autoimmune hepatitis","volume":"45","author":"Czaja","year":"2000","journal-title":"Dig Dis Sci"},{"key":"B173","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41598-017-18818-5","article-title":"Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis","volume":"8","author":"Diestelhorst","year":"2018","journal-title":"Sci Rep."},{"key":"B174","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus, Ann","volume":"75","author":"Von","year":"2016","journal-title":"Rheum Dis."},{"key":"B176","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/hep.30059","article-title":"Low dose interleukin-2 for refractory autoimmune hepatitis","volume":"68","author":"Lim","year":"2018","journal-title":"Hepatology"},{"key":"B177","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41591-018-0070-2","article-title":"A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism","volume":"24","author":"Trotta","year":"2018","journal-title":"Nat Med."},{"key":"B179","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"7492836","DOI":"10.1155\/2017\/7492836","article-title":"Mesenchymal stem cells as new therapeutic agents for the treatment of primary biliary cholangitis","volume":"2017","author":"Arsenijevic","year":"2017","journal-title":"Anal Cell Pathol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jgh.12029","article-title":"Pilot study of umbilical cord derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis","volume":"28","author":"Wang","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/ajt.15369","article-title":"Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity","volume":"19","author":"Cantarelli","year":"2019","journal-title":"Am J Transplant"},{"key":"B183","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nature11550","article-title":"Diversity, stability and resilience of the human gut microbiota","volume":"489","author":"Lozupone","year":"2012","journal-title":"Nature"},{"key":"B184","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaut.2013.07.001","article-title":"Role of the intestinal microbiome in liver disease","volume":"46","author":"Henao-Mejia","year":"2013","journal-title":"J Autoimmun"},{"key":"B185","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature10759","article-title":"Inflammasomes in health and disease","volume":"481","author":"Strowig","year":"2012","journal-title":"Nature"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nature07336","article-title":"Innate immunity and intestinal microbiota in the development of Type 1 diabetes","volume":"455","author":"Wen","year":"2008","journal-title":"Nature."},{"key":"B187","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ibd.21339","article-title":"Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases","volume":"17","author":"Frank","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"B188","first-page":"1500","article-title":"Fecal microbiota in early rheumatoid arthritis","volume":"35","author":"Vaahtovuo","year":"2008","journal-title":"J Rheumatol"},{"key":"B189","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hep.27927","article-title":"Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis","volume":"63","author":"Tabibian","year":"2016","journal-title":"Hepatology."},{"key":"B190","doi-asserted-by":"publisher","first-page":"e0198757","DOI":"10.1371\/journal.pone.0198757","article-title":"Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease","volume":"13","author":"Abe","year":"2018","journal-title":"PLoS ONE"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/hep.27998","article-title":"A novel humanized mouse model for autoimmune hepatitis and the association of gut microbiota with liver inflammation","volume":"62","author":"Yuksel","year":"2015","journal-title":"Hepatology."},{"key":"B192","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1084\/jem.20041035","article-title":"Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis","volume":"200","author":"Eksteen","year":"2004","journal-title":"J Exp Med."},{"key":"B193","doi-asserted-by":"publisher","first-page":"485","DOI":"10.4161\/gmic.29795","article-title":"Microbiome manipulation modifies sex-specific risk for autoimmunity","volume":"5","author":"Markle","year":"2014","journal-title":"Gut Microbes"},{"key":"B194","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ejphar.2017.07.012","article-title":"JKB-122 is effective, alone or in combination with prednisolone in Con A-induced hepatitis","volume":"812","author":"Hsu","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/nature24760","article-title":"Microbiota: a high-pressure situation for bacteria","volume":"551","author":"Relman","year":"2017","journal-title":"Nature"},{"key":"B196","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nature11868","article-title":"Sodium chloride drives autoimmune disease by the induction of pathogenic TH17cells","volume":"496","author":"Kleinewietfeld","year":"2013","journal-title":"Nature"},{"key":"B197","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","article-title":"The microbial metabolites, short-chain fatty acids, regulate colonic Tregs cell homeostasis","volume":"341","author":"Smith","year":"2013","journal-title":"Science"},{"key":"B198","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cellimm.2018.03.003","article-title":"High fiber dietary and sodium butyrate attenuate experimental autoimmune hepatitis through regulation of immune regulatory cells and intestinal barrier","volume":"328","author":"Hu","year":"2018","journal-title":"Cell Immunol."},{"key":"B199","first-page":"5153","article-title":"Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis","volume":"8","author":"Lin","year":"2015","journal-title":"Int J Clin Exp Pathol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fped.2019.00382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T04:37:04Z","timestamp":1568954224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fped.2019.00382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":199,"alternative-id":["10.3389\/fped.2019.00382"],"URL":"https:\/\/doi.org\/10.3389\/fped.2019.00382","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,20]]},"article-number":"382"}}